Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise

Dow Jones

Nov 18, 2025

By Kelly Cloonan

Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment.

The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share.

Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million.

The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication.

Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

November 17, 2025 16:20 ET (21:20 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584267461"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584267461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584267461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584267461","market":"hk","top_or_hot":-1,"title":"Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment. \n</p>\n<p>\n  The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share. \n</p>\n<p>\n  Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million. \n</p>\n<p>\n  The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication. \n</p>\n<p>\n  Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 16:20 ET (21:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-18 05:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment. \n</p>\n<p>\n  The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share. \n</p>\n<p>\n  Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million. \n</p>\n<p>\n  The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication. \n</p>\n<p>\n  Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 16:20 ET (21:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENTA","symbol_name":"Enanta Pharmaceuticals Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2584267461","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584267461","pubTimestamp":1763414400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment.The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share.Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million.The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication.Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ENTA":"Enanta Pharmaceuticals Inc."},"translate_title":"随着丙型肝炎治疗药物销售额的上升，Enanta Pharmaceuticals第四季度亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTA":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment. \n\n\n  The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share. \n\n\n  Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million. \n\n\n  The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication. \n\n\n  Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 16:20 ET (21:20 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}